Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Pediatric Pacemaker Implantation Technique

  • Author: Charles I Berul, MD; Chief Editor: Stuart Berger, MD  more...
 
Updated: Apr 01, 2014
 

Approach Considerations

Provide a thorough and adequate explanation of pacemaker implantation procedures to the patient. Document indications for permanent pacing and outline the plan for route of access. Make relevant surgical decisions after comprehensive consideration of the following factors:

  • Transvenous versus epicardial approach
  • Single-chamber pacing versus dual-chamber pacing versus cardiac resynchronization therapy (CRT)
  • Vascular access and continuity
  • Prepectoral versus submuscular pocket
  • Handedness of the patient and left-side versus right-side implantation
  • Presence of structural heart disease, intracardiac shunts, and obstruction to the right heart chambers
  • Relevant medical, surgical, and anesthesia history
  • Allergies
  • Risks of the procedure, including pacemaker-specific risks
  • Finite battery longevity, lead failure, and likely potential for reoperation
Next

Implantation of Pacemaker

A sterile environment is absolutely essential for implantation. Proper facilities include an operating room, a cardiac catheterization laboratory, or an electrophysiology laboratory. The implantation procedure may be performed with either general or local anesthesia, depending on the patient’s age and the planned route of implantation.

For the transvenous approach, one can perform either a cephalic vein cutdown or percutaneous subclavian (or axillary) vein puncture to access the venous system. Position a wire in the right heart with pacing leads positioned in the right atrium or ventricle. Testing is performed using cables to a pacing system analyzer, which can ascertain adequate sensing of intrinsic waves, capture thresholds, and lead impedances.

The generator is then connected to the leads, and a pacemaker pocket is fashioned either prepectorally or subpectorally, usually with blunt dissection, cauterization, or both. The generator is placed in the pocket, and the incision is closed in multiple layers.

Leaving a generous amount of slack in the lead to allow uncurling may reduce the risk of lead fracture or dislodgment with linear growth (see the image below). Studies have been performed to estimate the amount of intracardiac lead redundancy necessary to allow for anticipated growth.

Transvenous ventricular pacemaker in 2-year-old ch Transvenous ventricular pacemaker in 2-year-old child. Note abundant slack in lead to allow for growth.

The epicardial approach is typically performed via a subcostal or subxiphoid incision, a thoracotomy, or a sternotomy. The pacing leads are attached to epicardial surfaces and then tested for capture, sensing, and lead impedances. As with the transvenous approach, a pocket is created, typically in the subrectus region of the abdomen (or in the pectoral region), with subcutaneous tunneling of the leads from epicardial sites to the pocket.

As a rule, most patients remain hospitalized for 12-48 hours after the operation, depending on age, complexity, and route of access.

Aside from several weeks’ restriction from heavy lifting, extreme stretching of the accessed shoulder (for transvenous implants), and vigorous activities, patients may resume normal activities of daily living after the procedure. These restrictions are particularly important after passive lead implantation to avoid dislodgment. The incision must be kept clean and dry and typically heals within 7-10 days.

Antibiotic prophylaxis after the first 24 hours has not been demonstrated to reduce the risk of pacemaker system or pocket infection. Patients are instructed to immediately report any symptoms of possible infection.

For patients with newly implanted CRT devices, clinicians may choose to optimize the system (specifically the pacemaker timings) with the help of echocardiography.

Previous
Next

Complications

Complications involve immune response to artificial materials and response of the body to the pacemaker system.

Pacemaker generators are typically very reliable and have a low failure rate. The lithium iodide battery has a limited longevity of 5-15 years. Battery depletion is not a complication but a normal occurrence.

Pacing leads are more prone to failure, particularly in children.[19] Leads may fail at the conductor wires or in the insulation material (polyurethane or silicone). Lead failure typically results in inappropriate sensing or capture (ie, underpacing or overpacing).

Infection of the pacemaker system is a serious complication and almost always necessitates complete system removal, intravenous antibiotics, and system replacement at a remote site. However, in selected cases, pacemaker system infection can occasionally be effectively treated with a prolonged course of antibiotics, without system removal.

Twiddler syndrome is an interesting finding caused by repetitive and often unintentional twisting of the generator in the pacemaker pocket, causing lead dislodgment or fracture and pacemaker failure.[20] It is most commonly observed in patients with behavioral issues.

Significant vascular access challenges can also relate to congenital heart diseases and surgical corrections.

Finally, chronic right ventricular pacing over long periods (eg, decades) has been shown in a small group of patients to lead to decreased cardiac function.

Previous
 
 
Contributor Information and Disclosures
Author

Charles I Berul, MD Professor of Pediatrics and Integrative Systems Biology, George Washington University School of Medicine; Chief, Division of Cardiology, Children's National Medical Center

Charles I Berul, MD is a member of the following medical societies: American Academy of Pediatrics, Heart Rhythm Society, Cardiac Electrophysiology Society, Pediatric and Congenital Electrophysiology Society, American College of Cardiology, American Heart Association, Society for Pediatric Research

Disclosure: Received grant/research funds from Medtronic for consulting.

Chief Editor

Stuart Berger, MD Medical Director of The Heart Center, Children's Hospital of Wisconsin; Associate Professor, Department of Pediatrics, Section of Pediatric Cardiology, Medical College of Wisconsin

Stuart Berger, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, American College of Chest Physicians, American Heart Association, Society for Cardiovascular Angiography and Interventions

Disclosure: Nothing to disclose.

Acknowledgements

John W Moore, MD, MPH Professor of Clinical Pediatrics, Section of Pediatric Cardiology, Department of Pediatrics, University of California San Diego School of Medicine; Director of Cardiology, Rady Children's Hospital

John W Moore, MD, MPH is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, and Society for Cardiac Angiography and Interventions

Disclosure: Nothing to disclose.

Jeffrey Allen Towbin, MD, MSc, FAAP, FACC, FAHA Professor, Departments of Pediatrics (Cardiology), Cardiovascular Sciences, and Molecular and Human Genetics, Baylor College of Medicine; Chief of Pediatric Cardiology, Foundation Chair in Pediatric Cardiac Research, Texas Children's Hospital

Jeffrey Allen Towbin, MD, MSc, FAAP, FACC, FAHA is a member of the following medical societies: American Academy of Pediatrics, American Association for the Advancement of Science, American College of Cardiology, American College of Sports Medicine, American Heart Association, American Medical Association, American Society of Human Genetics, Cardiac Electrophysiology Society, New York Academy of Sciences, Society for Pediatric Research,Texas Medical Association, and Texas Pediatric Society

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

References
  1. Alexander ME, Cecchin F, Walsh EP, Triedman JK, Bevilacqua LM, Berul CI. Implications of implantable cardioverter defibrillator therapy in congenital heart disease and pediatrics. J Cardiovasc Electrophysiol. 2004 Jan. 15(1):72-6. [Medline].

  2. DeMaso DR, Lauretti A, Spieth L, et al. Psychosocial factors and quality of life in children and adolescents with implantable cardioverter-defibrillators. Am J Cardiol. 2004. 93:582-7. [Medline].

  3. Silka MJ, Bar-Cohen Y. Pacemakers and implantable cardioverter-defibrillators in pediatric patients. Heart Rhythm. 2006 Nov. 3(11):1360-6. [Medline].

  4. Smerup M, Hjertholm T, Johnsen SP, et al. Pacemaker implantation after congenital heart surgery: risk and prognosis in a population-based follow-up study. Eur J Cardiothorac Surg. 2005 Jul. 28(1):61-8. [Medline].

  5. Chintala K, Forbes TJ, Karpawich PP. Effectiveness of transvenous pacemaker leads placed through intravascular stents in patients with congenital heart disease. Am J Cardiol. 2005 Feb 1. 95(3):424-7. [Medline].

  6. Cecchin F, Frangini PA, Brown DW, et al. Cardiac Resynchronization Therapy (and Multisite Pacing) in Pediatrics and Congenital Heart Disease: Five Years Experience in a Single Institution. J Cardiovasc Electrophysiol. 2008 Sep 3. [Medline].

  7. Dubin AM, Janousek J, Rhee E, et al. Resynchronization therapy in pediatric and congenital heart disease patients: an international multicenter study. J Am Coll Cardiol. 2005 Dec 20. 46(12):2277-83. [Medline].

  8. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008 May 27. 51(21):e1-62. [Medline].

  9. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakersand antiarrhythmia devices: summary article: a report of the American College of Cardiology/AmericanHeart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee t. Circulation. 2002 Oct 15. 106(16):2145-61. [Medline].

  10. Gregoratos G, Cheitlin MD, Conill A. ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). J Am Coll Cardiol. 1998 Apr. 31(5):1175-209. [Medline].

  11. Horenstein MS, Karpawich PP. Pacemaker syndrome in the young: do children need dual chamber as the initial pacing mode?. Pacing Clin Electrophysiol. 2004 May. 27(5):600-5. [Medline].

  12. Mathony U, Schmidt H, Groger C, et al. Optimal maximum tracking rate of dual-chamber pacemakers required by children and young adults for a maximal cardiorespiratory performance. Pacing Clin Electrophysiol. 2005 May. 28(5):378-83. [Medline].

  13. Ovsyshcher IE, Hayes DL, Furman S. Dual-chamber pacing is superior to ventricular pacing: fact or controversy? [comment]. Circulation. 1998 Jun 16. 97(23):2368-70. [Medline].

  14. Silvetti MS, Drago F. Upgrade of single chamber pacemakers with transvenous leads to dual chamber pacemakers in pediatric and young adult patients. Pacing Clin Electrophysiol. 2004 Aug. 27(8):1094-8. [Medline].

  15. Fishberger SB, Wernovsky G, Gentles TL, et al. Long-term outcome in patients with pacemakers following the Fontan operation. Am J Cardiol. 1996 Apr 15. 77(10):887-9. [Medline].

  16. Noiseux N, Khairy P, Fournier A, Vobecky SJ. Thirty years of experience with epicardial pacing in children. Cardiol Young. 2004 Oct. 14(5):512-9. [Medline].

  17. Stojanov P, Vranes M, Velimirovic D, et al. Prevalence of venous obstruction in permanent endovenous pacing in newborns and infants: follow-up study. Pacing Clin Electrophysiol. 2005 May. 28(5):361-5. [Medline].

  18. Fortescue EB, Berul CI, Cecchin F, Walsh EP, Triedman JK, Alexander ME. Comparison of modern steroid-eluting epicardial and thin transvenous pacemaker leads in pediatric and congenital heart disease patients. J Interv Card Electrophysiol. 2005 Oct. 14(1):27-36. [Medline].

  19. Fortescue EB, Berul CI, Cecchin F, Walsh EP, Triedman JK, Alexander ME. Patient, procedural, and hardware factors associated with pacemaker lead failures in pediatrics and congenital heart disease. Heart Rhythm. 2004 Jul. 1(2):150-9. [Medline].

  20. Berul CI, Hill SL, Estes NA 3rd. A teenager with pacemaker twiddler syndrome. J Pediatr. 1997 Sep. 131(3):496-7. [Medline].

  21. Molina JE, Dunnigan AC, Crosson JE. Implantation of transvenous pacemakers in infants and small children. Ann Thorac Surg. 1995 Mar. 59(3):689-94. [Medline].

 
Previous
Next
 
Electrocardiogram reveals sinus atrial mechanism with complete atrioventricular block and ventricular paced rhythm.
Electrocardiogram illustrates 2-year-old child with third-degree atrioventricular block.
Electrocardiogram illustrates atrial-synchronous, ventricular paced rhythm.
Illustration of normal conduction system.
Transvenous ventricular pacemaker in 2-year-old child. Note abundant slack in lead to allow for growth.
Epicardial dual-chamber implantable cardioverter defibrillator in neonate with congenital complete atrioventricular block. Two bipolar suture-on leads (1 on atrium and 1 on ventricle) are attached to DDDR pacemaker in abdomen.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.